Medicaid Rx Spending Up 24% in 2014 With Expanded Eligibility, HCV Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
HCV drugs also contribute to 16.9% surge in Medicare Part D spending in 2014, CMS says in health expenditures review.
You may also be interested in...
Price Increases Accounted For Over Half Of Drug Spending Growth In 2015
CMS National Health Expenditures report finds continued double-digit growth rates for retail prescription drug spending in Medicare and Medicaid.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.